[go: up one dir, main page]

NO20061347L - Farmasoytisk formulering omfattende lanthanforbindelser - Google Patents

Farmasoytisk formulering omfattende lanthanforbindelser

Info

Publication number
NO20061347L
NO20061347L NO20061347A NO20061347A NO20061347L NO 20061347 L NO20061347 L NO 20061347L NO 20061347 A NO20061347 A NO 20061347A NO 20061347 A NO20061347 A NO 20061347A NO 20061347 L NO20061347 L NO 20061347L
Authority
NO
Norway
Prior art keywords
resulting
lanthanum
compound
compressing
tablet
Prior art date
Application number
NO20061347A
Other languages
English (en)
Other versions
NO342559B1 (no
Inventor
Josephine Christine Ferdinando
Robert Paul Haslam
Laura Anna Trespidi
Original Assignee
Shire Holdings Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34221462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061347(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Holdings Ag filed Critical Shire Holdings Ag
Publication of NO20061347L publication Critical patent/NO20061347L/no
Publication of NO342559B1 publication Critical patent/NO342559B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives en tyggbar lantanformulering omfattende en farmasøytisk effektiv mengde av en landtanforbindelse, og minst en tyggbar, farmasøytisk akseptabel eksipient. Det beskrives videre farmasøytiske formuleringer i form av en tablett eller et pulver omfattende en farmasøytisk effektiv mengde av en lantanforbindelse, fremstilt ved en fremgangsmåte omfattende trinnene: a) pulverblanding av lantanforbindelsen og minst en farmasøytisk akseptabel eksipient i en blander for å danne en blanding; eller b) pulverblanding av lantanforbindelsen og eksipienter, komprimering av den resulterende kombinasjon til et pluggmateriale eller valsekompaktering av den resulterende kombinasjon til et strengmateriale, og oppmaling av det fremstilte materialet til en frittrislende blanding; og c) å komprimere den resulterende blanding til en tablett eller fylle opp det resulterende materialet i en egnet beholder.
NO20061347A 2003-08-26 2006-03-24 Farmasøytisk formulering omfattende lantankarbonat og anvendelse av denne NO342559B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49756003P 2003-08-26 2003-08-26
US51707803P 2003-11-05 2003-11-05
PCT/CA2004/001563 WO2005018651A1 (en) 2003-08-26 2004-08-26 Pharmaceutical formulation comprising lanthanum compounds

Publications (2)

Publication Number Publication Date
NO20061347L true NO20061347L (no) 2006-05-15
NO342559B1 NO342559B1 (no) 2018-06-18

Family

ID=34221462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061347A NO342559B1 (no) 2003-08-26 2006-03-24 Farmasøytisk formulering omfattende lantankarbonat og anvendelse av denne

Country Status (29)

Country Link
US (2) US7465465B2 (no)
EP (4) EP2792363B1 (no)
JP (2) JP4896719B2 (no)
KR (1) KR100830764B1 (no)
CN (1) CN1871018B (no)
AT (2) ATE460169T1 (no)
AU (2) AU2004266050B2 (no)
BR (1) BRPI0413394A8 (no)
CA (1) CA2536959C (no)
CY (2) CY1110241T1 (no)
CZ (1) CZ17621U1 (no)
DE (2) DE602004025950D1 (no)
DK (5) DK2792363T3 (no)
EA (2) EA200970709A1 (no)
ES (4) ES2592803T3 (no)
FI (1) FI7568U1 (no)
HK (1) HK1084338A1 (no)
HU (2) HUE024906T2 (no)
IL (2) IL173755A0 (no)
IS (1) IS2893B (no)
MX (1) MXPA06002257A (no)
NO (1) NO342559B1 (no)
NZ (1) NZ545633A (no)
PL (4) PL2133084T3 (no)
PT (4) PT2172205E (no)
SG (1) SG145765A1 (no)
SI (4) SI2792363T1 (no)
WO (1) WO2005018651A1 (no)
ZA (1) ZA200602213B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
ES2362271T3 (es) * 2001-04-23 2011-06-30 Shire International Licensing B.V. Uso de carbonato de lantano para la prevención de la enfermedad de cálculo renal.
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
AU2004266050B2 (en) * 2003-08-26 2009-06-18 Takeda Pharmaceutical Company Limited Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
KR20070054191A (ko) * 2004-07-27 2007-05-28 샤이어 파마세우티컬, 인크. 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
AU2006279364A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Hyperphosphatemia in domestic animals: compositions and methods of treatment
WO2007022445A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
BRPI0815376A2 (pt) * 2007-07-31 2014-10-07 Cargill Inc Dextrose diretamente compresível
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
WO2009118760A2 (en) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition
EP2389070B1 (en) 2009-01-21 2013-07-31 Mylan Inc. Disintegrable formulations of lanthanum carbonate
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
AU2010313075A1 (en) * 2009-10-26 2012-05-31 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
KR101940207B1 (ko) 2010-05-12 2019-01-18 스펙트럼 파마슈티컬즈 인크 란탄 카보네이트 하이드록사이드, 란탄 옥시카보네이트 및 이들의 제조 및 사용 방법
EP2441436A1 (de) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
DE102012209411A1 (de) * 2012-06-04 2013-12-05 Fim Biotech Gmbh Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6093829B1 (ja) * 2015-10-02 2017-03-08 バイエル薬品株式会社 ランタン化合物を含む医薬組成物
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法
EP4061340A4 (en) * 2019-11-21 2023-08-09 Santa Farma Ilaç Sanayi A.S. ORAL SOLID PHARMACEUTICAL COMPOSITIONS WITH LANTANHANE CARBONATE OCTAHYDRATE
CN113244179B (zh) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 一种稳定性好的碳酸镧片剂及其制备方法和其应用
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
US4877735A (en) 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
DE3724188C2 (de) 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
JP2640570B2 (ja) * 1992-01-13 1997-08-13 ファイザー インク． 強度が増加した錠剤の製造
PL185332B1 (pl) 1994-05-20 2003-04-30 Janssen Pharmaceutica Nv Kompozycja przeciwrobacza dla zwierząt towarzyszących człowiekowi zawierająca flubendazol
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
JP3591886B2 (ja) 1994-09-05 2004-11-24 シーシーアイ株式会社 希土類元素集積微生物
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0008392D0 (en) 2000-04-05 2000-05-24 Unilever Plc Process for the production of a deodorant or antiperspirant product
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
JP2002047210A (ja) 2000-08-04 2002-02-12 Nihon Medi Physics Co Ltd 尿路結石防止用組成物
JP4612180B2 (ja) 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
JP4612183B2 (ja) 2000-12-27 2011-01-12 株式会社ヤクルト本社 皮膚外用組成物及びその製造方法
EP1344528B1 (en) 2000-12-19 2008-10-08 Kabushiki Kaisha Yakult Honsha External skin preparations and process for producing the same
US20020122823A1 (en) 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
ES2362271T3 (es) * 2001-04-23 2011-06-30 Shire International Licensing B.V. Uso de carbonato de lantano para la prevención de la enfermedad de cálculo renal.
GB0201607D0 (en) 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
CA2483827C (en) * 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
AU2003282867A1 (en) 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
AU2004266050B2 (en) 2003-08-26 2009-06-18 Takeda Pharmaceutical Company Limited Pharmaceutical formulation comprising lanthanum compounds
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7545784B2 (en) * 2004-02-11 2009-06-09 Yahoo! Inc. System and method for wireless communication between previously known and unknown users
GB2430368B (en) 2004-03-30 2009-08-26 Ilypsa Inc Methods and compositions for treatment of ion imbalances
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
KR20070054191A (ko) * 2004-07-27 2007-05-28 샤이어 파마세우티컬, 인크. 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
WO2009118760A2 (en) 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition

Also Published As

Publication number Publication date
CN1871018A (zh) 2006-11-29
NZ545633A (en) 2009-07-31
SG145765A1 (en) 2008-09-29
IL235371B (en) 2018-08-30
EP1660104A4 (en) 2006-10-18
NO342559B1 (no) 2018-06-18
AU2004266050B2 (en) 2009-06-18
CN1871018B (zh) 2011-11-02
CY1110241T1 (el) 2015-01-14
SI2172205T1 (sl) 2014-10-30
EP2172205B1 (en) 2014-06-18
JP2007503400A (ja) 2007-02-22
EP1660104B1 (en) 2010-03-10
ES2592803T3 (es) 2016-12-01
PT2172205E (pt) 2014-07-17
PL1660104T3 (pl) 2010-08-31
EP2792363B1 (en) 2016-06-29
IL173755A0 (en) 2006-07-05
DK200600252U1 (da) 2007-01-12
BRPI0413394A8 (pt) 2016-03-08
PL2133084T3 (pl) 2015-08-31
AU2009202429B2 (en) 2012-03-22
KR100830764B1 (ko) 2008-05-20
IS2893B (is) 2014-09-15
ATE460169T1 (de) 2010-03-15
DE202004021169U1 (de) 2007-03-01
PT1660104E (pt) 2010-06-15
CA2536959C (en) 2011-08-02
EP1660104A1 (en) 2006-05-31
HK1084338A1 (en) 2006-07-28
PT2133084E (pt) 2015-04-16
HUE029382T2 (en) 2017-02-28
US20050079135A1 (en) 2005-04-14
ES2343354T3 (es) 2010-07-29
AU2009202429A1 (en) 2009-07-09
PT2792363T (pt) 2016-09-26
US20090017133A1 (en) 2009-01-15
FIU20060387U0 (fi) 2006-09-22
EA200970709A1 (ru) 2010-04-30
DK200600252U4 (da) 2007-11-23
PL2172205T3 (pl) 2015-01-30
SI2792363T1 (sl) 2016-11-30
HUE024906T2 (en) 2016-02-29
EP2133084A2 (en) 2009-12-16
CA2536959A1 (en) 2005-03-03
FI7568U1 (fi) 2007-07-17
EP2172205A1 (en) 2010-04-07
DK2172205T3 (da) 2014-07-14
EP2792363A1 (en) 2014-10-22
AT9809U1 (de) 2008-04-15
DK2792363T3 (da) 2016-09-26
ES2532389T3 (es) 2015-03-26
DK2133084T3 (en) 2015-04-13
KR20060118420A (ko) 2006-11-23
ZA200602213B (en) 2009-04-29
WO2005018651A1 (en) 2005-03-03
SI1660104T1 (sl) 2010-08-31
EP2133084B1 (en) 2015-02-18
JP2010248247A (ja) 2010-11-04
DK1660104T3 (da) 2010-06-21
ES2478258T3 (es) 2014-07-21
PL2792363T3 (pl) 2017-01-31
EA200600479A1 (ru) 2006-08-25
BRPI0413394A (pt) 2006-10-17
IS8353A (is) 2006-03-15
EP2133084A3 (en) 2010-02-03
CZ17621U1 (cs) 2007-06-25
EA012798B1 (ru) 2009-12-30
MXPA06002257A (es) 2006-05-17
AU2004266050A1 (en) 2005-03-03
SI2133084T1 (sl) 2015-07-31
US7465465B2 (en) 2008-12-16
CY1118211T1 (el) 2017-06-28
DE602004025950D1 (de) 2010-04-22
JP4896719B2 (ja) 2012-03-14

Similar Documents

Publication Publication Date Title
NO20061347L (no) Farmasoytisk formulering omfattende lanthanforbindelser
WO2006078593A3 (en) Direct compression formulation and process
WO2009002084A3 (en) Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
TW200640502A (en) Tablets with improved drug substance dispersibility
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
WO2002013793A3 (en) Method of making tablets and tablet compositions produced therefrom
WO1998058629A3 (en) Preparation of pharmaceutical compositions
WO2004016244A3 (en) Pharmaceutical compositions for buccal delivery of pain relief medications
EP1702612B1 (en) Soft capsule containing butylphthalide and its preparation procedure
NZ510583A (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
WO2004108162A3 (en) Controlled release pharmaceutical composition
EP2563329B1 (en) Orally disintegrating tablet containing acarbose
IL172602A0 (en) Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]- octane-3-carboxylic acid deriv atives
HUP0004363A2 (hu) Miltefosint tartalmazó orális szilárd gyógyszerkészítmények leishmaniasis kezelésére
MY137846A (en) Processes for the preparation of oral dosage formulations of modafinil
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
WO2007052307A3 (en) Stable solid oral dosage forms of valsartan
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2007010369B1 (en) Sustained release formulation of alprazolam
WO2006101462A3 (en) Pharmaceutical preparation comprising perindopril erbumine and method of preparation and stabilisation thereof
WO2010019279A8 (en) Pharmaceutical compositions configured to deter dosage form splitting
JPH0480885B2 (no)
WO2004014318A3 (en) Levothyroxine compositions and methods

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: SHIRE BIOPHARMACEUTICALS HOLDINGS IRELAND LTD, JE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

CREP Change of representative

Representative=s name: BRYN AARFLOT AS, STORTINGSGATA 8, 0161 OSLO, NORGE